Balaxi Pharmaceuticals Limited

June 30, 2023

To, Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Dear Sir/Madam,

Subject: Intimation of closure of trading window

Pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct to regulate, monitor and report trading of designated persons, the trading window for dealing in securities of the Company will be closed from July 1, 2023 till 48 hours after the declaration of Unaudited Financial Results for the quarter ending June 30, 2023.

Accordingly, all the Designated Persons and their immediate relatives are advised not to trade in securities of the Company during the period of closure of Trading Window.

The date of the meeting of Board of Directors for declaration of Unaudited Financial Results of the Company for the quarter ending June 30, 2023 will be intimated in due course.

This is for your information and records.

Yours Faithfully,

For Balaxi Pharmaceuticals Limited

Udayan Shukla (Company Secretary & Compliance Officer) Membership No.: F11744

Registered Office: Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096 CIN: L25191TG1942PLC121598 Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in